LifeVantage announces results from MindBody GLP-1 System trial

LifeVantage (LFVN) announced results from a human clinical trial performed on the new MindBody GLP-1 System. Results from the trial included a 140% average increase in GLP-1 levels in the body leading to an average weight loss of nine pounds in eight weeks and up to 25 pounds in 12 weeks in participants. Production of GLP-1 in the body declines due to age, poor diet, stress, or other lifestyle factors. The decline can cause cravings, false hunger, and weight gain. The MindBody GLP-1 System uses ingredients to directly activate natural GLP-1 production in L-cells, supporting that activation indirectly by optimizing the gut microbiome to create short-chain fatty acids and fuel production. The 12-week human clinical trial began in early June and set out to investigate if, through these mechanisms of action, the MindBody GLP-1 System could holistically and sustainably increase GLP-1 hormone levels in overweight adults, without unwanted side effects. The study was conducted by independent researchers at Lighthouse Research. Sixty subjects ages 31-78 years with a BMI of 25 were randomized into three groups: a control group with no product use, a group using the MindBody GLP-1 System without diet and exercise guidelines, and a group using the MindBody GLP-1 System with diet and exercise guidelines. Subjects were evaluated every four weeks. Visits included anthropometric and biometric measurements, before and after photographs, food behavior questionnaires, and blood work for GLP-1 analysis. Twelve-week findings from the human trial include: 140% increase of GLP-1 on average; 92% of participants lost weight, with an average of 11 pounds; 92% saw a reduction in total body fat, with up to a 5.5% decrease; 71% experienced a reduction in visceral fat, with up to a 27% decrease; 100% of subjects who lost weight maintained or saw an increase in muscle %, with up to a 2.7% increase. No side effects were reported, including gastrointestinal issues. In addition to these physical results, participants reported notable changes in their relationship with food: 85% agreed their food cravings decreased; 95% agreed their sugar cravings decreased; 96% agreed their portion sizes at each meal decreased and 85% agreed they now eat for health, not emotional reasons; 82% felt more in control of their relationship with food. The clinical trial builds on in vitro research, which found that the MindBody GLP-1 System significantly increased GLP-1 production in L-cells by activating key genes. The in vitro study also revealed a 38% reduction in DPP-4 gene expression, allowing more GLP-1 to remain active within the body, and a 53% increase in GLP1R expression, which promotes the creation of GLP-1 cell receptors, further enhancing the body’s ability to use GLP-1.